Evidence map›Paper›PMID 37734160›Full record

ArticleThe American journal of drug and alcohol abuse2024

Are you thinking what I'm thinking? Defining what we mean by "polysubstance use."

Amanda M Bunting, Riley Shearer, Ashley N Linden-Carmichael, Arthur Robin Williams, Sandra D Comer, Magdalena Cerdá, Jennifer Lorvick

Open access · greenAbstract read
In one paragraph

Article in The American journal of drug and alcohol abuse, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 35 citations in OpenAlex.

  1. Co-Use of Some Substances Associated With Higher Doses in Adolescents: Findings From the Adolescent Brain Cognitive Development Study.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Amanda M BuntingDepartment of Population Health, New York University Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-2103-9655
Riley ShearerDivision of Health Policy and Management, University of Minnesota, Minneapolis, MN, USA.
Ashley N Linden-CarmichaelEdna Bennett Pierce Prevention Research Center, The Pennsylvania State University, University Park, PA, USA.ORCID 0000-0001-8187-6538
Arthur Robin WilliamsDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York, NY, USA.ORCID 0000-0002-7380-6203
Sandra D ComerDepartment of Psychiatry, Columbia University, New York, NY, USA.
Magdalena CerdáDepartment of Population Health, New York University Grossman School of Medicine, New York, NY, USA.
Jennifer LorvickCommunity Health and Implementation Research Program, RTI International, Berkeley, CA, USA.
New York University · USColumbia University · USColumbia University Irving Medical Center · USPennsylvania State University · USRTI International · USUniversity of Minnesota · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine ComponentsUG3DA047711 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI COMER, SANDRA D, PRAVETONI, MARCO · 2018 to 2019
$9.4M
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine ComponentsUH3DA047711 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI SANDRA D. COMER, Marco Pravetoni · 2023 to 2026
$7.3M
Phase 1 and 2 studies of sublingual dexmedetomidine, an alpha 2 adrenergic agonist, for treating opioid withdrawalUG3DA056247 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI COMER, SANDRA D, LEVIN, FRANCES RUDNICK · 2022 to 2022
$3.3M
The Cascade of Care for Medicaid-Enrolled Youth with Opioid Use DisorderR01DA057566 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI Scott Evan Hadland, Arthur R Williams · 2022 to 2026
$2.9M
A mixed-methods study of polysubstance use to inform opioid overdose preventionR01DA049761 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI LORVICK, JENNIFER · 2020 to 2024
$1.8M
Development of a novel polysubstance assessment tool for vulnerable subpopulationsK01DA053435 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BUNTING, AMANDA M · 2021 to 2025
$909k
Simultaneous Alcohol and Marijuana Use: Momentary Influences and ConsequencesK01AA026854 · NIAAA · PENNSYLVANIA STATE UNIVERSITY, THE · PI LINDEN-CARMICHAEL, ASHLEY NICOLE · 2019 to 2023
$826k
The OUD Cascade of Care and Critical Outcomes: Longitudinal Linkage with Opioid UseR01DA059042 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI WILLIAMS, ARTHUR R · 2023 to 2023
$711k
Characteristics and outcomes for hospitalized patients with methamphetamine and opioid co-use: Identifying opportunities for hospital-based addiction services tailored to co-useF30DA057775 · NIDA · UNIVERSITY OF MINNESOTA · PI Riley Shearer · 2023 to 2026
$171k
Polysubstance Use SymposiumR13DA057083 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BUNTING, AMANDA M · 2022 to 2022
$25k
NIAAA NIH HHS K01 AA026854NIDA NIH HHS F30 DA057775NIDA NIH HHS K01 DA053435NIDA NIH HHS R01 DA049761NIDA NIH HHS R01 DA057566NIDA NIH HHS R01 DA059042NIDA NIH HHS R13 DA057083NIDA NIH HHS UG3 DA047711NIDA NIH HHS UG3 DA056247NIDA NIH HHS UH3 DA047711NIGMS NIH HHS T32 GM008244
6 · The paper itself

Abstract

The rise in drug overdoses and harms associated with the use of more than one substance has led to increased use of the term "polysubstance use" among researchers, clinicians, and public health officials. However, the term retains no consistent definition across contexts. The current authors convened from disciplines including sociology, epidemiology, neuroscience, and addiction psychiatry to propose a recommended definition of polysubstance use. An iterative process considered authors' formal and informal conversations, insights from relevant symposia, talks, and conferences, as well as their own research and clinical experiences to propose the current definition. Three key concepts were identified as necessary to define polysubstance use: (1) substances involved, (2) timing, and (3) intent. Substances involved include clarifying either (1) the number and type of substances used, (2) presence of more than one substance use disorder, or (3) primary and secondary substance use. The concept of timing is recommended to use clear terms such as simultaneous, sequential, and same-day polysubstance use to describe short-term behaviors (e.g., 30-day windows). Finally, the concept of intent refers to clarifying unintentional use or exposure when possible, and greater attention to motivations of polysubstance use. These three components should be clearly defined in research on polysubstance use to improve consistency across disciplines. Consistent definitions of polysubstance use can aid in the synthesis of evidence to better address an overdose crisis that increasingly involves multiple substances.

Indexed as

Drug OverdoseSubstance-Related DisordersHumansMotivationPublic HealthconceptmeasurementPolysubstance usesubstance use disorder

Identifiers

PMID37734160
PMCPMC10939915
OpenAlexW4386915133

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.